^
BIOMARKER:

Chr del(17p)

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Chr del(17p)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A2
SOHO 2022 - 6 days - (New B)
Chr del(17p)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive
:
A2
SOHO 2022 - 6 days - (New B)
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
ibrutinib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
rituximab + idelalisib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
acalabrutinib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
idelalisib + ofatumumab
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
ofatumumab
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
rituximab
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + rituximab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
ofatumumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
duvelisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + alemtuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
lenalidomide
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
lenalidomide
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + lenalidomide
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
rituximab + lenalidomide
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
alemtuzumab
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
pembrolizumab
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
nivolumab
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
duvelisib
Sensitive
:
A2